According to this framework, a typical AD trajectory is marked by tau biomarker positivity (biological stage ≥ B) which typically precedes the MCI or dementia stage (clinical stage ≥ 3; Fig. 3A, pathway (1)). The gene discussed is MAPT; the disease is Alzheimer disease.